Re:Theranos Trouble: A First Person Account
by neurotech1 on Sunday October 18, 2015 @08:00PM
(#10410379)
The lack of peer-reviewed research for Theranos is a valid criticism. The method and technology used in other labs likely is peer-reviewed at some level, so not disagreeing on that point.
What I am suggesting is that other labs do have variances in results, on certain lab tests. The OP did say that there was a 7% variation in Platelet results in successive days, using the Stanford lab.
Quest Diagnostics have had previous settlements with DoJ for "inaccurate and unreliable" lab test kits. [0]
[0] http://www.justice.gov/opa/pr/quest-diagnostics-pay-us-302-m...
Since you 99% sure that other labs have problems, are you suggesting that all the other labs rely on technology that also have a dearth of peer-review published results?
[1] http://jama.jamanetwork.com/article.aspx?articleid=2110977
> As of January 5, 2015, a search in PubMed using Theranos as a search term identified affiliations for only 2 unrelated articles coauthored by Theranos Inc employees, although these 2 reports do not offer insights about their company.
[2] http://www.newyorker.com/magazine/2014/12/15/blood-simpler
> Clarke argues that finger-stick blood tests aren’t reliable for clinical diagnostic tests; because the blood isn’t drawn from a vein, the sample can be contaminated by lanced capillaries or damaged tissue. Holmes strongly disagrees: “We have data that show you can get a perfect correlation between a finger stick and a venipuncture for every test that we run.” When I asked for evidence, I was sent a document by Daniel P. Edlin, Theranos’s senior product manager, titled “Select Data.” It purported to show favorable results from numerous comparison tests. I asked Edlin if the tests had been conducted by an independent third party. He replied by e-mail: “The clinical tests were conducted by a combination of Theranos and external labs,” but he wouldn’t say which ones.
> When I asked Holmes for evidence that her tests were independently audited, she said that there have been “tens” of audits and “external third-party comparisons” of Theranos’s tests, including those done by the hospital groups that are adopting its finger-prick tests and the pharmaceutical companies that have contracted with Theranos for testing their products. Holmes says that Theranos is certified in forty-eight states, with two more applications pending, under the federal Clinical Laboratory Improvement Amendments of 1988. Under the amendments, laboratories like hers must be certified before they can perform tests for the general public, and their performance is evaluated three times a year by the College of American Pathologists. Holmes also pointed me to a pilot study published by Hematology Reports, an online-only peer-reviewed journal; she is listed as a co-author. The report, released in April, concluded that Theranos tests “correlated highly with values obtained” from standard lab tests.